Socioeconomic value of intervention for chronic pain
Socioeconomic value of intervention for chronic pain
复制标题
慢性疼痛干预的社会经济价值
作者：
T. Takura;M. Shibata;Shinsuke Inoue;Y. Matsuda;H. Uematsu;Keiko Yamada;T. Ushida
PurposeThe目的本研究的目的是检查疼痛治疗的成本效益在两个疼痛centersinJapan.MethodsThe研究人群包括91例接受各种治疗慢性疼痛，分为三类：（1）药物，（2）药物+神经阻滞，（3）其他方式（运动和/或疼痛教育）。使用疼痛残疾评估量表（PDAS）评分、医院焦虑和抑郁量表（HADS）评分、疼痛灾难化量表（PCS）评分和EQ-5D评分评估疼痛。首先，通过评价EQ-5D评分与其他疼痛相关评价工具评分的相关性，评估EQ-5D评分的可靠性，然后评价疼痛治疗的成本效益。对医疗费用的评估是根据医院管理处提供的数据进行的，而这些数据又是根据国家保健计划的医疗费用进行的。质量调整生命年（QALY）值从EQ-5D评分计算，转换为12个月，然后用于成本效益分析沿着与医疗feeds.ResultsAccording最近的IASP分类，慢性神经性疼痛（41）比慢性原发性疼痛（37例）或慢性肌肉骨骼疼痛（27例）。EQ-5D评分与PDAS、HADS和PCS评分之间存在显著相关性，这证明了EQ-5D评分的可靠性。疼痛治疗3个月后，观察到HADS、PCS和EQ-5D评分显著改善。根据估计的年度医疗费用和QALY的成本效益计算显示，平均值为45，879美元± 103，155每QALY（中位数为16，903美元），表明足够的社会经济utility.ConclusionBased根据我们的研究结果，EQ-5D是可靠的评估慢性疼痛患者。医学经济平衡是适当的，在日本的两个综合疼痛中心提供的所有治疗。
PurposeThe purpose of this study was to examine the cost-effectiveness of pain treatments in two pain centers in Japan.MethodsThe study population comprised 91 patients receiving various treatments for chronic pain, which were divided into three categories: (1) medication, (2) medication + nerve block, and (3) other modalities (exercise and/or pain education). Pain was assessed using the Pain Disability Assessment Scale (PDAS) score, Hospital Anxiety and Depression Scale (HADS) score, Pain Catastrophizing Scale (PCS) score, and EQ-5D score. First, the reliability of the EQ-5D score first assessed by evaluating the correlation this score with those of the other pain-related evaluation instruments, and then the cost effectiveness of the pain treatments was evaluated. Evaluation of medical costs was based on data provided from the Management Services of the hospital, which in turn were based on national health scheme medical treatment fees. The quality-adjusted life year (QALY) value was calculated from the EQ-5D score, converted to 12 months, and then used for cost-benefit analysis along with medical treatment fees.ResultsAccording to the recent IASP classification, more patients had chronic neuropathic pain (41) than chronic primary pain (37 patients) or chronic musculoskeletal pain (27 patients). There was a significant correlation between the EQ-5D score and the PDAS, HADS, and PCS scores, which demonstrated the reliability of the EQ-5D score. Significant improvement in the HADS, PCS, and EQ-5D scores was noted after 3 months of pain treatment. Calculation of the cost-effectiveness based on the estimated annual medical treatment cost and QALY revealed a mean value of US $45,879 ± 103,155 per QALY (median US $16,903), indicating adequate socioeconomic utility.ConclusionBased on our results, the EQ-5D is reliable for evaluating chronic pain in patients. The medico-economic balance was appropriate for all treatments provided in two comprehensive pain centers in Japan.